Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Releases New Drug GMPs; Domestic Consolidation Expected To Accelerate

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's State FDA released its long-awaited good manufacturing practices guidelines for pharmaceutical products Feb. 12, which will begin to be implemented in all new drug manufacturing sites in March

You may also be interested in...



Manufacturers Unable to Make Minor Changes to Products in China

A lack of a reporting mechanism for minor or moderate changes to approved pharmaceuticals in China makes it difficult for pharmaceutical manufacturers to make lifecycle improvements to products marketed there. Long review timelines and unclear expectations during inspections further complicate the picture.

A Closer Look: With Only 60% Of China’s Sterile Drug Makers Passing New GMP Standard, What’s Next?

Only 60% of sterile drug manufacturers passed the new GMP standard in China, as smaller companies chose to quit the market.

China FDA Bans Korean Drug After Disagreement On Overseas Inspection

In a sign of increasing confidence by Chinese regulators, CFDA banned an injectable antibiotic from Daewoong Pharmaceutical after the company rejected an overseas inspection request due to ongoing upgrades at a Korean plant.

Related Content

UsernamePublicRestriction

Register

SC077162

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel